Background
==========

Many therapies such as surgery, chemical or physical approaches have been used for treatment of HCC; however, the outcome is still poor. Cancer immunotherapy is considered to be one of the promising strategies in recent years.

Methods
=======

Expression of CTAs genes including MAGE A3, MAGE A4, MAGE C2 and NY-ESO-1 genes was detected with reverse transcription polymerase chain reaction (RT-PCR) in HCC tissues and corresponding adjacent non-cancerous tissues from 71 HCC patients.

Results
=======

87.3% of HCC tumor tissue samples expressed at least 1 CTAs. HCC adjacent non-cancerous tissues did not express CTAs. 78.9% tumor tissue samples expressed MAGE-A3 mRNA, 33.8% samples expressed MAGE-A4 mRNA, 74.6% samples expressed MAGE-C2 mRNA and 14.1% samples expressed NY-ESO-1 mRNA. The expression of CTAs showed correlation with Ki67(r=0.27, P=0.02) and tumor stages (r=0.31, P=0.01), no correlation with clinical parameters such as age, gender, ALT, HLA-A2 positive, CA125, CA199, HBV or HCV infection and tumor size (P\>0.05). The expression of MAGE-A3 showed correlation with the high expressions of CEA in serum (r=0.30, P=0.03), AFP in serum (r=0.26, P=0.03) and lymph node metastases (r=0.30, P=0.01).

Conclusion
==========

Our findings demonstrate the cancer testis expression of CTAs genes show correlations with tumor stages and proliferation and may represent useful targets for tumor specific immunotherapy in HCC patients.

###### 

Clinicopathological characteristics of the HCC patients

  Characteristics      No.patients   \%
  -------------------- ------------- ------
  Gender               71            
  Male                 54            76.1
  Female               17            23.9
  Age(y)                             
  \<55                 47            66.2
  ≥55                  24            33.8
  ALT(IU/ml)                         
  \<80                 61            85.9
  ≥80                  10            14.1
  HLA A2                             
  Positive             41            57.7
  Negative             30            42.3
  AFP(ng/ml)                         
  ≤10                  30            42.3
  \>10                 41            57.7
  Tumor size(cm)                     
  ≤5                   43            60.6
  \>5                  28            39.4
  TNM classification                 
  I or II              34            47.9
  III or IV            37            52.1
  Etiology                           
  HBV                  45            63.4
  HCV                  6             8.5
  No                   20            28.1
  Ki67(%)                            
  ≤40                  30            42.3
  \>40                 41            57.7
  CTAs                               
  Positive             62            87.3
  Negative             9             12.7
  Average age(year)    53.7±11.5     
